Novo Holdings, an international life science investor, announced a £50 million investment in Oxford Nanopore Technologies, a UK Listed company behind a new generation of molecular sensing technology based on nanopores.
Oxford Nanopore has developed a new generation of molecular analysis technology used for DNA/RNA sequencing. The technology is designed to offer rich data including epigenetics, rapid insights through real-time workflows and portable formats, in a way that is accessible and affordable.
The technology is used increasingly in clinical and applied industrial settings including biopharma. Access to fast, information-rich molecular information has the potential to play a critical role across the biopharma industry, from drug discovery to commercialization.
In particular, direct RNA sequencing can enable biologics manufacturing and quality control processes for an emerging class of mRNA-based products, potentially replacing multiple technologies with a single, streamlined platform. Furthermore, the generation of epigenetic data (variation in DNA information that can influence many diseases such as cancer) in large-scale studies can promote discoveries.
Dr. Daniel Mahony, Senior Partner, Growth Investments, Novo Holdings, said, “Oxford Nanopore has made impressive ongoing progress to advance its technology platform and gain commercial traction. This investment underscores our belief in Oxford Nanopore’s platform and its expanding opportunity in biopharmaceuticals, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new drug therapies.”
Dr. Gordon Sanghera, Chief Executive Officer, Oxford Nanopore added, “Novo Holdings is one of the world’s top life sciences investors, and we are delighted to welcome them as a long-term shareholder. The Novo Holdings team brings deep knowledge of the biopharmaceutical market, including biomanufacturing, a key growth area for Oxford Nanopore. We look forward to their support given our commitment to biopharma as one of our strategic growth vectors.”
https://www.contractpharma.com/contents/view_breaking-news/2024-08-01/novo-holdings-invests-50m-in-oxford-nanopore/9769
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
